Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release platform for therapeutic proteins which was partnered with Bristol Myers Squibb (BMS).

In 2005, Olivier founded Adocia with his father, Gérard Soula, and his brother, Rémi Soula. Olivier has held successively the position of Director of Research and Development, Deputy Chief Executive Officer and then, Chief Executive Officer since 2023. He was instrumental in the signing of 4 major partnerships which represented more than 150 million dollars of revenue with Eli Lilly and with Tonghua Dongbao.

Olivier is co-author of more than 40 patents on protein delivery and has worked for more than 20 years in the field of innovative insulin formulations.

Valérie Danaguezian worked for 4 years as an external auditor at Calan Ramolino & Associés (Deloitte & Touche).

In 1991, she joined Sanofi Pasteur where she was in charge of the financial consolidation of the Group; she was then promoted to Director of R&D controlling.

In 2003, she joined Flamel Technologies as Financial Director, a position she held for 3 years. She joined Adocia in 2006 as Financial Director and member of Adocia Committee management.